Strong Performance in EMEA, LatAm, and APAC
The EMEA, LatAm, and APAC regions performed well within the company's medium-term 4% to 6% organic sales growth guidance, with strong volume growth in these regions.
Gross Margin and Cash Flow Improvement
The company reported a 160 basis points improvement in gross margin and strong cash flow, contributing to organic profit growth.
Oral Health Market Share Gains
Oral Health segment showed strong growth with market share gains, including a 0.5 share point increase in the U.S.
Investment in A&P and Innovation
A&P spend increased by 6.8% to 20.8%, with investments focused on innovation, premiumization, and expanding reach to lower-income consumers.
Successful Innovation and ROI Improvement
The company successfully rolled out innovations such as Nasal Mist on Otrivin and Panadol Dual Action, and improved ROI by 4%.
Asia Pacific Volume Growth
Volume growth in Asia Pacific accelerated from 3.3% in Q1 to 3.9% in Q2, with 2/3 of growth in Q2 coming from volume.